Price List - Yuviwel - Growth Stimulating Agents - NA.xlsx

XLSX spreadsheet 46 KB Posted

Attached to
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Solicitation number
HT9402-26-Q-9203
Issued by

About this file

This is a Price List template for the Department of War (DoW) Pharmacy Uniform Formulary Blanket Purchase Agreement (BPA) for Growth Stimulating Agents to be reviewed at the May 6-7, 2026 P&T Committee meeting. The solicitation HT9402-26-Q-9203 requests quotations from pharmaceutical manufacturers for newly approved growth stimulating agents, with quotes due by April 27, 2026. The price list contains ten newly approved drug appendices that require manufacturers to submit pricing for two formulary scenarios: Uniform Formulary Before Step Therapy and Non-Formulary After Step Therapy. Manufacturers must provide pricing per NDC package size and per unit of measure, with the same unit price required across all available package sizes within a given dispensing venue (Military Treatment Facility and Mail Order).

The document includes three pricing mechanisms: Blanket Purchase Agreement (BPA) pricing, Additional Discount Program (ADP) with non-FAMP discounts, and ADP with Wholesale Acquisition Cost (WAC) discounts. For BPA submissions, manufacturers must complete quote review checklists and fully executed signature pages. The formulary notes indicate that Prior Authorization may apply and that agents with average net ingredient costs exceeding $1500 per four weeks of therapy may be considered for Tier 2 before step therapy classification. The price list is a template with all ten drug appendices currently showing "NO QUOTE" status, and manufacturers must confirm their intent to submit or decline quotations. All pricing information must be submitted by the April 27, 2026 deadline for consideration by the DoW P&T Committee.

View the file

Other files

Show all 12

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

BPA

UF BPA NDC Price List for the May 2026 DoW P&T Meeting
DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoW P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoW P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: No Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.

Based on available government prices and historical information, the band of prices for net ingredient cost may trigger formulary considerations.

Scenario: Uniform Formulary and/or Tier 2 before step therapy may be considered if ingredient cost is ≤ $1500 average per 4 weeks of therapy.

Agents with RFQ not submitted or selected may be designated non-step preferred.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The price per unit of measure for a given dosage form and strength (each, gram, mL, etc.) of the pharmaceutical agent will be the same for all available package sizes (e.g., 30s, 100s, 1000s) within a given dispensing venue.

Blanket Purchase Agreement Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#2DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#3DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#5DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

Blanket Purchase Agreement Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#9DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote
Blanket Purchase Agreement Appendix – Newly Approved Drug
#10DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeMilitary Treatment Facility & Mail Order
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsPrice per NDCPackage SizePrice per Unit
1 or more agent(s) before step
Scenario 1242GHNAG0UFBS1MUniform Formulary
Before Step Therapy1 or moreNO QUOTE
242GHNAG0NFAS1MNon-Formulary
After Step Therapy1 or moreNO QUOTE
If cell highlights red, please confirm intent not to submit a quote

ADP (non-FAMP Discount)

UF ADP Appendix for the May 2026 DoW P&T Meeting
DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoW P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoW P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: No Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.

Based on available government prices and historical information, the band of prices for net ingredient cost may trigger formulary considerations.

Scenario: Uniform Formulary and/or Tier 2 before step therapy may be considered if ingredient cost is ≤ $1500 average per 4 weeks of therapy.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

* Total Calculated Refund Per FCP is calculated as: ((non-FAMP-FCP)+(non-FAMP*Y%)) = Total Calculated Refund **Based on the most recent annual non-FAMP (reported to the Department of Veterans Affairs) from which the current annual Federal Ceiling Price (FCP) calculated ceiling is derived. The current annual FCP and the annual non-FAMP from which it is derived will be applicable to all prescriptions filled during a calendar year. The quoted additional refund percentage will remain static during the life of the agreement but the most recent annual non-FAMP, and thus the calculated refund, may change each calendar year.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote
Additional Discount Program Appendix – Newly Approved Drug
#5DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote
Additional Discount Program Appendix – Newly Approved Drug
#10DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary Category DescriptionOne of (x) Number of Brand AgentsNon-FAMP Price of Drug Per FCP Package**Additional Offered Refund Per FCP Package**Current Annual Federal Ceiling Price Per FCP Package**Standard Refund Per FCPTotal Calculated Retail Refund Per FCP Package*
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

ADP (WAC Discount)

UF ADP Appendix for the May 2026 DoW P&T Meeting
DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
Formulary Notes
Class Note(s): Prior Authorization (PA) may apply. Agents may be identified as possible candidates for special reimbursement methods, amounts, and procedures to encourage use of high-value products and discourage use of low-value products. The DoW P&T Committee may recommend consideration of preferential status to any non-generic pharmaceutical agent by treating it for purposes of cost sharing as a generic product (Tier 1). Similarly, the DoW P&T Committee may identify candidates to recommend for complete exclusion from the TRICARE pharmacy benefit program.

Step Therapy Addendum: No Grandfathering: a prior authorization process requires new patients to complete an adequate trial of the step-preferred agent(s) before a non-step-preferred agent is provided to the patient at any MTF, Retail, or Mail point of service.

Based on available government prices and historical information, the band of prices for net ingredient cost may trigger formulary considerations.

Scenario: Uniform Formulary and/or Tier 2 before step therapy may be considered if ingredient cost is ≤ $1500 average per 4 weeks of therapy.

Notes to Manufacturers: Do not forget to submit the Quote Review Checklist and fully executed signature pages, along with quote information.

The Wholesale Acquisition Cost (WAC) is obtained from First Databank via daily price updates; it is maintained at the dispensing unit level to five (5) decimal places. If the WAC changes during a calendar quarter, an average WAC will be calculated on a daily weighted basis (per unit only).

WAC is ONLY used for products that do not have a FCP, such as diabetic supplies (i.e., test strips), and can also be applied to covered drugs.

*The quoted WAC Discount percentage will remain static during the life of the agreement.

Additional Discount Program Appendix – Newly Approved Drug

#1DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#2DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#3DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#4DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#5DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#6DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#7DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#8DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#9DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

Additional Discount Program Appendix – Newly Approved Drug

#10DoW Uniform Formulary Class:GROWTH STIMULATING AGENTSP&T Committee Meeting:May 6-7, 2026
DoW Uniform Formulary Subclass:N/AQuotes due:April 27, 2026
NDC NumberDrug NameStrengthDosage FormPackage SizeTRICARE RETAIL REFUND
Formulary ScenariosCondition Set #Formulary CategoryOne of (x) Number of Brand AgentsWAC Price of DrugWAC Discount*Total Calculated Retail Refund per Package
1 or more agent(s) before step
Scenario 1242GHNAG0T2BS1MTier 2
Before Step1 or more
242GHNAG0T3AS1MTier 3
After Step1 or more
If cell highlights red, please confirm intent not to submit a quote

File details come from the government source that posted it. Updated .